Top 10 Oncology Capital Raises and Investors in the U.S. – October 16th – November 15th, 2025
Several interesting transactions closed in the Oncology sector over the past two weeks. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PIPE
-
- Neuphoria Therapeutics, that develops therapies that addresses the complex needs of individuals affected by neuropsychiatric disorders, received $3.28 million of development capital from Lynx1 Capital Management through a private placement.
- Tango Therapeutics, biotechnology company that discovers novel drug targets and delivers the next generation of precision medicine for the treatment of cancer, received $197.06 million of development capital from Nextech Invest, Boxer Capital, The Invus Group, TCG Crossover Management, Farallon Capital Management, Logos Capital, Woodline Partners, Balyasny Asset Management, Adage Capital Management and Nantahala Capital Management through a private placement.
Merger/Acquisition
-
- L2P Research, clinical research and development company that offers preclinical, oncology and toxicology services, was acquired by NJ Bio, a subsidiary of Cohance.
- New York Stem Cell Foundation, disease research institute and philanthropic organization, that accelerates cures for the major diseases through stem cell research, was acquired by The Jackson Laboratory.
Later Stage VC
-
- ClevelandDx, blood-based cancer diagnostics platform that improves clarity in disease detection, raised an additional $14.42 million of Series E1 venture funding.
- Jupiter Biomedical Research, disease-curing therapeutics that treats brain cancer and other epidermoid tumors, raised $500,000 of venture funding.
Early Stage VC
-
- GreenJay Therapeutics, drug formulations for hematological diseases, raised $1 million of Series A venture funding.
- Neok Bio, biotechnology research and development that transforms the treatment of cancer by solving therapeutic challenges and improving patient outcomes, raised $75 million of Series A venture funding from ABL Bio and other investors.
Seed
-
- Cellens, cell surface scanning platform that assists oncologists in performing noninvasive detection of bladder cancer, raised $6.44 million of Seed-1 funding from BrightEdge, SOSV and IndieBio.
- Jabez Biosciences, cancer therapeutic that improves treatment outcomes while maintaining simplicity, raised $250,510 of seed funding from investors.
#castleplacement #capitalraising #privateequity #venturecapital #investment #Oncology
Gary Levy
Managing Director
Over 30 years in financial services, including senior roles at Citi, Ivy Asset Management (an Affiliate of BNY) and TIAA. Founder and President of Biltmore Savings Consultants, a provider of B2B technology solutions to improve operations. Author of published book "21 Ways to Improve Your Business Operations." MBA - Strategic Business Management from Hofstra University’s Frank G. Zarb School of Business. BS (with a concentration in Business, Management and Economics) from SUNY Empire State College. Series 7, 63 and 79 licenses.
- Email: glevy@castleplacement.com
- (C) (516) 457-0104
 Gary LevyManaging Director |
Please contact me if you have any questions or would like to discuss your capital raise:
Email: glevy@castleplacement.com
(C) (516) 457-0104
Send us a message:
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
